RU2019103297A - Гастроретентивные составы для перорального введения и пути их применения - Google Patents

Гастроретентивные составы для перорального введения и пути их применения Download PDF

Info

Publication number
RU2019103297A
RU2019103297A RU2019103297A RU2019103297A RU2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A
Authority
RU
Russia
Prior art keywords
dosage unit
pharmaceutical dosage
cannabinoid
polymer
gastroretentive
Prior art date
Application number
RU2019103297A
Other languages
English (en)
Russian (ru)
Other versions
RU2019103297A3 (cg-RX-API-DMAC7.html
Inventor
Надав НАВОН
Ронни РАЙНБЕРГ
Йохай ЯКОВСОН
Original Assignee
Интек Фарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59388117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019103297(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Интек Фарма Лтд. filed Critical Интек Фарма Лтд.
Publication of RU2019103297A publication Critical patent/RU2019103297A/ru
Publication of RU2019103297A3 publication Critical patent/RU2019103297A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019103297A 2016-07-11 2017-07-11 Гастроретентивные составы для перорального введения и пути их применения RU2019103297A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662360744P 2016-07-11 2016-07-11
US62/360,744 2016-07-11
PCT/IL2017/050783 WO2018011798A1 (en) 2016-07-11 2017-07-11 Oral gastroretentive formulations and uses thereof

Publications (2)

Publication Number Publication Date
RU2019103297A true RU2019103297A (ru) 2020-08-11
RU2019103297A3 RU2019103297A3 (cg-RX-API-DMAC7.html) 2020-11-06

Family

ID=59388117

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019103297A RU2019103297A (ru) 2016-07-11 2017-07-11 Гастроретентивные составы для перорального введения и пути их применения

Country Status (17)

Country Link
US (1) US20190224118A1 (cg-RX-API-DMAC7.html)
EP (1) EP3481371A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019527208A (cg-RX-API-DMAC7.html)
KR (1) KR20190026799A (cg-RX-API-DMAC7.html)
CN (1) CN109414403A (cg-RX-API-DMAC7.html)
AU (1) AU2017296351A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018077541A2 (cg-RX-API-DMAC7.html)
CA (1) CA3027700A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019000643A2 (cg-RX-API-DMAC7.html)
IL (1) IL264065A (cg-RX-API-DMAC7.html)
MX (1) MX2019000348A (cg-RX-API-DMAC7.html)
NZ (1) NZ750422A (cg-RX-API-DMAC7.html)
PH (1) PH12019500061A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019103297A (cg-RX-API-DMAC7.html)
SG (2) SG10202100182TA (cg-RX-API-DMAC7.html)
WO (1) WO2018011798A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201900275B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
BR102018002843A2 (pt) * 2018-02-09 2019-08-27 Prati, Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
WO2020037410A1 (en) * 2018-08-20 2020-02-27 Hexo Operations Inc. Cannabis-infused product with enhanced cannabinoid profile user experience
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
US20210177740A1 (en) * 2019-12-11 2021-06-17 Joel Studin Transpore delivery of cannabinoid and uses thereof
EP4084790A1 (en) * 2020-01-02 2022-11-09 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Floating drug delivery systems comprising cannabinoids
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
TW202430130A (zh) * 2022-10-18 2024-08-01 大陸商南京三迭紀醫藥科技有限公司 用於胃滯留的口服藥物劑型
CN117224522B (zh) * 2023-11-15 2024-02-23 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
DK2997953T3 (en) 2006-01-18 2019-04-15 Intec Pharma Ltd ADMINISTRATION ORAL ADMINISTRATION
DK2276473T3 (en) * 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US20140017303A1 (en) * 2010-11-01 2014-01-16 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof

Also Published As

Publication number Publication date
JP2019527208A (ja) 2019-09-26
CA3027700A1 (en) 2018-01-18
ZA201900275B (en) 2020-05-27
NZ750422A (en) 2021-10-29
BR112018077541A2 (pt) 2019-04-30
SG11201811209QA (en) 2019-01-30
WO2018011798A1 (en) 2018-01-18
PH12019500061A1 (en) 2019-10-14
MX2019000348A (es) 2019-03-28
RU2019103297A3 (cg-RX-API-DMAC7.html) 2020-11-06
SG10202100182TA (en) 2021-02-25
AU2017296351A1 (en) 2019-02-28
EP3481371A1 (en) 2019-05-15
CN109414403A (zh) 2019-03-01
KR20190026799A (ko) 2019-03-13
CO2019000643A2 (es) 2019-04-30
IL264065A (en) 2019-01-31
US20190224118A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP2019527208A5 (cg-RX-API-DMAC7.html)
JP6325148B2 (ja) 注意欠陥障害の処置のための方法および組成物
US9980902B2 (en) Method for treating intestinal fibrosis
US9999651B2 (en) Composition comprising oil drops
ES2360423T3 (es) Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal.
JP4865945B2 (ja) 経口の延長放出性医薬品剤形
JP5911969B2 (ja) 心臓血管障害の治療方法
KR20100014629A (ko) 타크로리무스의 변형제형
JP2014012692A (ja) 食物の摂取から独立した消化器疾患の治療方法
JP2018500353A (ja) 回腸−空腸薬物送達用組成物
JP2007528901A5 (cg-RX-API-DMAC7.html)
CN109414403A (zh) 口服胃滞留制剂及其用途
US20170119680A1 (en) Extended release film-coated capsules
JP2020510000A (ja) フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤
WO2009148990A1 (en) Pulsatile release of valsartan
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
RU2577164C2 (ru) Таблетки с регулируемым по месту и времени высвобождением глюкокортикоида в желудочно-кишечном тракте
US11052048B2 (en) Esomeprazole-containing complex capsule and preparation method therefor
TW201711683A (zh) 含有達方吡啶的緩釋口服劑型及其用途
AU2017252407A1 (en) Oral pharmaceutical compositions of nicotinamide
RU2021102950A (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
TW201609196A (zh) 控制釋放製劑及其製備方法
EP3145500A1 (en) Celecoxib formulations useful for treating colorectal cancer
HK40006608A (en) Esomeprazole-containing complex capsule and preparation method therefor
JP2021528483A (ja) 下部胃腸管への医薬の送達のための剤形

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210920